These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29376993)

  • 1. [Divasa in the treatment and prevention of cerebrovascular diseases].
    Shavlovskaya OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(12):111-115. PubMed ID: 29376993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Perspectives of the novel drug divaza in the treatment of chronic cerebral ischemia].
    Tanaeva KK; Dugina IuL; Kachaeva EV; Epshteĭn OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(9):100-4. PubMed ID: 25473662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Cognitive Impairment and the Role of Demographic Factors in Disease Progression: The Final Results of the Russian Observational Program "DIAMANT".
    Parfenov VA; Zhivolupov SA; Poverennova IE; Nesterova MV; Ushakova SE; Zhukova NG; Glazunov AB; Nikulina KV; Alexandrov MV; Lapatukhin VG; Zhestikova MG
    Eur Neurol; 2020; 83(6):591-601. PubMed ID: 33202402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy of divasa in the early recovery period of ischemic stroke].
    Mudrova OA; Schekolova NB; Borikov FA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(3 Pt 2):48-54. PubMed ID: 27296802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tthe efficacy and safety of drug therapy divaza in patients with chronic cerebral ischemia].
    Fateeva VV; Shumakher GI; Vorob'eva EN; Khoreva MA; Voskanyan LR
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):32-37. PubMed ID: 28374690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Divaza for the Correction of Oxidative Disturbances in Patients with Cerebral Atherosclerosis: A Randomized Controlled Trial.
    Lashch NU; Kamchatnov PR; Fedorova TN; Muzychuk OA; Khacheva KK; Pizova NV; Malygin AU; Shavlovskaya OA; Fateeva VV; Nikulina KV; Abrosimov АV; Gerasimova YA; Glushkov KS; Lebedeva AV
    Cerebrovasc Dis; 2021; 50(4):472-482. PubMed ID: 34044407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Results of multicenter study of efficacy and safety of divaza in the treatment of the asthenic and mild to moderate cognitive disorders in elderly and senile subjects].
    Parfenov VА; Kamchatnov PR; Vorobyova ОV; Gustov АV; Glushkov КS; Doronina ОB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):43-50. PubMed ID: 29053120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An experience of using divasa in the treatment of cerebrovascular insufficiency].
    Chukanova EI; Bogolepova AN; Chukanova AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):17-23. PubMed ID: 26356393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of cognitive impairment in patients with chronic cerebral ischemia: the results of observational Russian program DIAMANT].
    Parfenov VA; Zhivolupov SA; Nikulina KV; Poverennova IE; Lapatuhin VG; Zhestikova MG; Zhukova NG; Glazunov AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(6):15-23. PubMed ID: 30040796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrandrine ameliorates cognitive impairment via inhibiting astrocyte-derived S100B activation in a rat model of chronic cerebral hypoperfusion.
    Chen L; Chen L; Lv Y; Cui Z; Bei G; Qin G; Zhou J; Ge T
    Neurol Res; 2013 Jul; 35(6):614-21. PubMed ID: 23561481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible role and application of fMRI in the screening of release-active drugs.
    Duma SN; Rezakova MV; Mazhirina KG; Petrovskii ED; Pokrovskii MA; Dzhafarova OA; Savelov AA; Shtark MB; Epstein OI
    Bull Exp Biol Med; 2015 Feb; 158(4):453-7. PubMed ID: 25708324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults.
    Barchukov VV; Zhavbert ES; Dugina YL; Epstein OI
    Bull Exp Biol Med; 2015 Nov; 160(1):61-3. PubMed ID: 26608378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Nitric oxide: from the mechanism of action to pharmacological effects in cerebrovascular diseases].
    Fateeva VV; Vorobyova OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):131-135. PubMed ID: 29171501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Levels of S100b and NSE Proteins in Patients with Non-Transfusion-Dependent Thalassemia as Biomarkers of Brain Ischemia and Cerebral Vasculopathy.
    Kanavaki A; Spengos K; Moraki M; Delaporta P; Kariyannis C; Papassotiriou I; Kattamis A
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29244749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute negative coupling of endothelial nitric oxide to endothelin-1 release: Support from nitric oxide synthase inhibitors?
    Yoon S; Zuccarello M; Rapoport RM
    Int J Cardiol; 2016 Jan; 202():646-8. PubMed ID: 26451792
    [No Abstract]   [Full Text] [Related]  

  • 16. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms.
    Nishimura M; Izumiya Y; Higuchi A; Shibata R; Qiu J; Kudo C; Shin HK; Moskowitz MA; Ouchi N
    Circulation; 2008 Jan; 117(2):216-23. PubMed ID: 18158361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with the glycogen synthase kinase-3beta inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus.
    Collino M; Thiemermann C; Mastrocola R; Gallicchio M; Benetti E; Miglio G; Castiglia S; Danni O; Murch O; Dianzani C; Aragno M; Fantozzi R
    Shock; 2008 Sep; 30(3):299-307. PubMed ID: 18323734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pentapeptide monocyte locomotion inhibitory factor protects brain ischemia injury by targeting the eEF1A1/endothelial nitric oxide synthase pathway.
    Zhang Y; Chen J; Li F; Li D; Xiong Q; Lin Y; Zhang D; Wang XF; Yang P; Rui YC
    Stroke; 2012 Oct; 43(10):2764-73. PubMed ID: 22829547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cerebral markers of endothelial dysfunction in chronic brain ischemia].
    Fateeva VV; Vorob'eva OV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(4):107-111. PubMed ID: 28617391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geranylgeranylacetone protects against cerebral ischemia and reperfusion injury: HSP90 and eNOS phosphorylation involved.
    He D; Song X; Li L
    Brain Res; 2015 Mar; 1599():150-7. PubMed ID: 25514333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.